GENOR BIOPHARMA DL-00002 Cash Flow-to-Debt Ratio
GENOR BIOPHARMA DL-00002 cash flow-to-debt ratio. GENOR BIOPHARMA DL-00002 (67N0) has a Cash Flow-to-Debt Ratio of -0.88x as of December 2024, meaning its operating cash flow of €-121.98 Million could theoretically repay -1% of its total liabilities (€138.05 Million) in one year. See GENOR BIOPHARMA DL-00002 financial flexibility index to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of GENOR BIOPHARMA DL-00002 (2021–2024)
Cash flow-to-debt ratio of GENOR BIOPHARMA DL-00002 from 2021 to 2024. Historical debt coverage capacity for GENOR BIOPHARMA DL-00002 across 4 annual periods. Also explore GENOR BIOPHARMA DL-00002 net asset momentum to track the company's year-over-year net asset growth rate.
GENOR BIOPHARMA DL-00002 Cash Flow-to-Debt Ratio by Year (2021–2024)
GENOR BIOPHARMA DL-00002 cash flow-to-debt ratio by year from 2021 to 2024. Year-by-year debt coverage analysis for GENOR BIOPHARMA DL-00002. For the full cash flow conversion analysis, see cash flow conversion of GENOR BIOPHARMA DL-00002.
| Year | CF-to-Debt Ratio | Operating CF (EUR) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -0.88x | €-121.98 Million | €138.05 Million | ▲ +46.8% |
| 2023 | -1.66x | €-425.12 Million | €256.18 Million | ▲ +11.0% |
| 2022 | -1.86x | €-577.61 Million | €309.87 Million | ▼ -10.5% |
| 2021 | -1.69x | €-623.74 Million | €369.73 Million | — |